In this episode, Mac and Lin discuss the challenges of managing exercise with automated insulin delivery systems.

https://www.diabettech.com/insulin/exercise-insulin-and-automation-the-challenges/

In this episode, we discover that Lin also has type 1 and Mac and Lin discuss the head to head study between the Abbott Libre3 and Dexcom G7 study published in the Journal of Diabetes Science and Technology in March and highlight some of the challenges with it.

https://www.diabettech.com/cgm/welcome-to-the-wild-wild-west-the-cgm-head-to-head-study/

This episode discusses the findings a small study looking at incretin-based therapy used by people with type 1 diabetes who are also using Open Source Automated delivery systems.

In this episode, Mac and Lin dig into the pharmacokinetics of incretins and how they might affect glucose management in type 1 diabetes.

Original Source:

https://wp.me/p7O2EL-2t0

This episode discusses a couple of posts on diabettech.com that dive into the data derived from CGM, pump and smart watch and offers some ideas on how that might help with diabetes management.

Sources:

https://www.diabettech.com/biological-data/diabetes-and-data-what-more-can-we-learn-part-1/

https://www.diabettech.com/biological-data/diabetes-and-data-what-more-can-we-learn-part-2/

This episode looks at Loop and AndroidAPS, published studies on their performance and a study on pigs that compared the algorithms and discussed why options are important and how these open source solutions are safe.

Source Data at:

https://pubmed.ncbi.nlm.nih.gov/33226840/

https://www.nejm.org/doi/full/10.1056/NEJMoa2203913

https://www.diabettech.com/artificial-pancreas/automated-insulin-delivery-why-choice-matters/

A look at the differences between the types of pump and some of the non-obvious reasons why you might want to choose one or the other.

To note: Google's AI wasn't quite aware of what tunneling is...

https://www.diabettech.com/patch-pump/to-patch-pump-or-not-to-patch-pump-that-is-the-question/

This episode features a discussion on GLP1-RAs, what they do physiologically and how they might affect Type 1 Diabetes.